Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 251-260

  Rougier, P ^a   Bugat, R ^a   Douillard, J Y ^a   Culine, S ^a   Suc, E ^a   Brunet, P ^a   Becouarn, Y ^a   Ychou, M ^a   Marty, M ^a   Extra, J M ^a   Bonneterre, J ^a   Adenis, A ^a   Seitz, J F ^a   Ganem, G ^a   Namer, M ^a   Conroy, T ^a   Negrier, S ^a   Merrouche, Y ^a   Burki, F ^a   Mousseau, M ^a   Herait, P ^a   Mahjoubi, M ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031014627     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.251     Document Type: Article

References (36)

1. Cunningham D, Findlay M: The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A:2077-2079, 1993
2. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
3. De Gramont A, Bosset JF, Milan C, et al: A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUFOL1d) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 14:455, 1995 (abstr)
4. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 10:904-911, 1992
5. Scheithauer W, Rosen H, Kornek G, et al: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752-755, 1993
6. Bertrand M, Doroshow JH, Multhauf P, et al: High dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: A phase II study. J Clin Oncol 4:1058-1061, 1986
7. Leong L, Doroshow J, Akman S, et al: Phase II trial of 5-FU and high dose folinic acid (HDFA) with cisplatin (CDDP) and dipyridamole (DP) in advanced colorectal cancer. Proc Am Soc Clin Oncol 8:383, 1989 (abstr)
8. Ahlgren JD, Trocki O, Gullo JJ, et al: Protracted infusion of 5-FU with weekly low dose cisplatin as a second line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Cancer Invest 9:27-33, 1991
9. Delap R, Bordurian E, Nazzaro D, et al: PALA plus 5FU in colorectal cancer: Pilot clinical study of a convenient outpatient treatment regimen. Proc Am Assoc Cancer Res 34:1694, 1993 (abstr)
10. Izzo J, Cvitkovic E, Zarba J, et al: Low dose 5FU continuous infusion (FuCL) in advanced colorectal cancer (ACC): Clinical evidence for reversal of acquired/intrinsic resistance to 5-FU or 5-FU folinic (FuFo). Ann Oncol 3:76, 1992 (suppl 5, abstr)
11. Brienza S, Levi F, Valori VM, et al: Intensified (every 2 weeks) chronotherapy with 5-fluorouracil (5-FU) folinic acid (FA) and oxaliplatin (L-OHP) in previously treated patients (pts) with metastatic colorectal cancer. Proc Am Soc Clin Oncol 12:577, 1993 (abstr)
12. Creemers GJ, Lund B, Verweij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994
13. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
14. Tanizawa A, Fujimori A, Fujimori Y, et al: Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86:836-842, 1994
15. Chen AY, Liu LF: DNA topoisomerases: Essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34:191-218, 1994
16. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
17. Shimada Y, Rothenberg M, Hilsenbeck SG, et al: Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5:20-26, 1994
18. Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumor in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74, 1988
19. Chen AY, Yu C, Potmesil M, et al: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991
20. Noonan KE, Beck C, Holzmayer TA, et al: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160-7164, 1990
21. De Forni M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994
22. Abigerges D, Chabot GG, Armand J, et al: Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
23. Catimel G, Chabot GG, Guastella JP, et al: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every 3 weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995
24. Abigerges D, Armand JP, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
25. Conti JA, Kemeny N, Saltz L, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
26. Pilot HC, Wender D, O'Connell MJ, et al: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 13:573, 1994 (abstr)
27. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
28. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, new camptothecin derivative, in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 10:408, 1991 (abstr)
29. Shimada Y, Yashino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
30. Hryniuk WM: The importance of dose intensity in outcome of chemotherapy: Important advances in oncology, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, pp 121-142
31. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
32. Deitch EA: The role of intestinal barrier failure and bacterial translocation in the development of systemic infection and multiple organ failure. Arch Surg 125:403-404, 1990
33. Berg RD: Bacterial translocation from the gastrointestinal tract. J Med 23:217-244, 1992
34. Erlichman C, Fine S, Wong A, et al: A randomised trial of fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 6:469-475, 1989
35. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomised phase III trial. J Clin Oncol 7:1419-1426, 1989
36. Cohen AH, Minsky BD, Schilsky RL: Colon cancer, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA, Lippincott, 1993, pp 929-977